Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D09CVV
|
||||
Former ID |
DNC013482
|
||||
Drug Name |
NORSTEPHALAGINE
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [551362] | ||
Structure |
Download2D MOL |
||||
Formula |
C18H17NO3
|
||||
Canonical SMILES |
COC1=C2CCNC3C2=C(C4=CC=CC=C4C3)C5=C1OCO5
|
||||
InChI |
1S/C18H17NO3/c1-20-16-12-6-7-19-13-8-10-4-2-3-5-11(10)15(14(12)13)17-18(16)22-9-21-17/h2-5,13,19H,6-9H2,1H3/t13-/m1/s1
|
||||
InChIKey |
TYZKUSBTFHNPMV-CYBMUJFWSA-N
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Dopamine D1 receptor | Target Info | Inhibitor | [528616] | |
Sodium-dependent dopamine transporter | Target Info | Inhibitor | [551362] | ||
Pathway Interaction Database | Alpha-synuclein signaling | ||||
PathWhiz Pathway | Dopamine Activation of Neurological Reward System | ||||
WikiPathways | Hypothetical Network for Drug Addiction | ||||
Monoamine GPCRs | |||||
GPCRs, Class A Rhodopsin-like | |||||
Genes and (Common) Pathways Underlying Drug Addiction | |||||
GPCR ligand binding | |||||
GPCR downstream signalingWP727:Monoamine Transport | |||||
NRF2 pathway | |||||
Dopaminergic Neurogenesis | |||||
Parkinsons Disease Pathway | |||||
Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | |||||
Neurotransmitter Clearance In The Synaptic Cleft | |||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.